Breast Cancer Unmasks Latent P. A. H. Susceptibility 01/29/26
Welcome to Cardiology Today â Recorded January 29, 2026. This episode summarizes 5 key cardiology studies on topics like glycated haemoglobin and drug-eluting stents. Key takeaway: Breast Cancer Unmasks Latent P. A. H. Susceptibility.
Article Links:
Article 1: Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial. (Journal of the American College of Cardiology)
Article 2: Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study. (Circulation)
Article 3: Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension. (Circulation)
Article 4: GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. (European heart journal)
Article 5: T cells in acute and chronic myocarditis: from diagnosis to treatment. (European heart journal)
Full episode page: https://podcast.explainheart.com/podcast/breast-cancer-unmasks-latent-p-a-h-susceptibility-01-29-26/
đ Featured Articles
Article 1: Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41194754
Summary: The REC-CAGEFREE I trial found that drug-coated balloon angioplasty with rescue stenting did not achieve noninferiority compared to intended drug-eluting stent implantation for treating de novo lesions in coronary artery disease. This concrete outcome was observed at the two-year follow-up. The data therefore demonstrated that the drug-coated balloon strategy was not equivalent to drug-eluting stents for these patients.
Article 2: Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41608826
Summary: The Master@Heart study confirmed that middle-aged and older endurance athletes exhibit an increased prevalence of coronary artery disease on coronary computed tomography angiography compared to healthy controls, despite having similarly low cardiovascular risk profiles. This observational cross-sectional analysis then utilized objective wearable-derived training load data to investigate its impact on coronary artery disease risk. The study’s novel approach addressed the previously unknown impact of objective training load measurements on cardiovascular outcomes in this athletic population. This represents a key advancement in quantifying training exposure more accurately than traditional self-reported data.
Article 3: Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41603037
Summary: M. P. R. 2-Related Susceptibility to Pulmonary Hypertension. This study revealed that breast cancer unmasks a latent susceptibility to pulmonary arterial hypertension associated with bone morphogenetic protein receptor type two (B. M. P. R. 2) mutations. Researchers found that these B. M. P. R. 2 mutations, known to cause heritable pulmonary arterial hypertension, also play a role in tumor-suppressive functions. The findings link these two diseases, disproportionately affecting women, through the genetic role of B. M. P. R. 2 alterations. This provides novel insights into the complex interplay between genetic predispositions and cancer development influencing cardiovascular health.
Article 4: GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41609518
Summary: L. P. minus 1 R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. This study utilized two-sample cis-Mendelian randomization to investigate the causal effects of glucagon-like peptide one receptor activation on heart failure risk. The findings suggested novel beneficial effects of G. L. P. minus 1 R agonists on heart failure risk that extend beyond their known impacts on glucose control and weight reduction. Glycated haemoglobin reduction served as a surrogate biomarker in this analysis, providing a new perspective on the mechanisms by which these agonists confer cardioprotection. The data therefore indicated that the cardiovascular benefits of G. L. P. minus 1 R agonists are likely multifactorial.
Article 5: T cells in acute and chronic myocarditis: from diagnosis to treatment.
Journal: European heart journal
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41605248
Summary: This article elucidated the critical role of T cells in the pathogenesis of both acute and chronic myocarditis, providing insights from diagnosis to treatment. It highlighted the emergence of newer etiologies for myocarditis, including those linked to immune checkpoint inhibitors and chronic inflammatory and genetic diseases. The content underscored the evolving understanding of immune cell infiltration and cardiomyocyte damage in myocarditis. The findings informed comprehensive strategies for identifying T-cell mediated myocarditis and guiding targeted immunotherapies.
đ Transcript
Today’s date is January 29, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial. The REC-CAGEFREE I trial found that drug-coated balloon angioplasty with rescue stenting did not achieve noninferiority compared to intended drug-eluting stent implantation for treating de novo lesions in coronary artery disease. This concrete outcome was observed at the two-year follow-up. The data therefore demonstrated that the drug-coated balloon strategy was not equivalent to drug-eluting stents for these patients.
Article number two. Wearable-Derived Training Load and Coronary Atherosclerosis in Middle-Aged and Older Athletes and Physically Active Controls: A New Perspective From the Master@Heart Study. The Master@Heart study confirmed that middle-aged and older endurance athletes exhibit an increased prevalence of coronary artery disease on coronary computed tomography angiography compared to healthy controls, despite having similarly low cardiovascular risk profiles. This observational cross-sectional analysis then utilized objective wearable-derived training load data to investigate its impact on coronary artery disease risk. The study’s novel approach addressed the previously unknown impact of objective training load measurements on cardiovascular outcomes in this athletic population. This represents a key advancement in quantifying training exposure more accurately than traditional self-reported data.
Article number three. Breast Cancer Reveals Latent B. M. P. R. 2-Related Susceptibility to Pulmonary Hypertension. This study revealed that breast cancer unmasks a latent susceptibility to pulmonary arterial hypertension associated with bone morphogenetic protein receptor type two (B. M. P. R. 2) mutations. Researchers found that these B. M. P. R. 2 mutations, known to cause heritable pulmonary arterial hypertension, also play a role in tumor-suppressive functions. The findings link these two diseases, disproportionately affecting women, through the genetic role of B. M. P. R. 2 alterations. This provides novel insights into the complex interplay between genetic predispositions and cancer development influencing cardiovascular health.
Article number four. G. L. P. minus 1 R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization. This study utilized two-sample cis-Mendelian randomization to investigate the causal effects of glucagon-like peptide one receptor activation on heart failure risk. The findings suggested novel beneficial effects of G. L. P. minus 1 R agonists on heart failure risk that extend beyond their known impacts on glucose control and weight reduction. Glycated haemoglobin reduction served as a surrogate biomarker in this analysis, providing a new perspective on the mechanisms by which these agonists confer cardioprotection. The data therefore indicated that the cardiovascular benefits of G. L. P. minus 1 R agonists are likely multifactorial.
Article number five. T cells in acute and chronic myocarditis: from diagnosis to treatment. This article elucidated the critical role of T cells in the pathogenesis of both acute and chronic myocarditis, providing insights from diagnosis to treatment. It highlighted the emergence of newer etiologies for myocarditis, including those linked to immune checkpoint inhibitors and chronic inflammatory and genetic diseases. The content underscored the evolving understanding of immune cell infiltration and cardiomyocyte damage in myocarditis. The findings informed comprehensive strategies for identifying T-cell mediated myocarditis and guiding targeted immunotherapies.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
glycated haemoglobin, drug-eluting stents, coronary artery disease, cardiovascular risk, drug-coated balloon angioplasty, T cells, cardioprotection, tumor-suppressive functions, Mendelian randomization, B. M. P. R. 2 mutations, breast cancer, wearable-derived training load, glucagon-like peptide one receptor agonists, chronic myocarditis, genetic susceptibility, immune checkpoint inhibitors, de novo lesions, endurance athletes, coronary computed tomography angiography, percutaneous coronary intervention, coronary atherosclerosis, myocarditis, heart failure, acute myocarditis, pulmonary arterial hypertension.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow